
PMC:7243778 / 27661-28601
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
684 | 370-374 | Gene | denotes | CDR3 | Gene:8163 |
685 | 444-448 | Gene | denotes | ACE2 | Gene:59272 |
686 | 165-173 | Species | denotes | SARS-CoV | Tax:694009 |
687 | 177-185 | Species | denotes | MERS-CoV | Tax:1335626 |
688 | 245-255 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
689 | 281-289 | Species | denotes | patients | Tax:9606 |
690 | 710-718 | Species | denotes | SARS-CoV | Tax:694009 |
691 | 832-842 | Species | denotes | SARS-Cov-2 | Tax:2697049 |
692 | 924-934 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
693 | 83-93 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
694 | 843-846 | Gene | denotes | ACE | Gene:1636 |
695 | 700-706 | Chemical | denotes | CR3022 | |
696 | 896-902 | Chemical | denotes | CR3022 | |
697 | 113-121 | Disease | denotes | infected | MESH:D007239 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T125 | 0-8 | Body_part | denotes | Antibody | http://purl.org/sig/ont/fma/fma62871 |
T126 | 122-128 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T127 | 320-328 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T128 | 353-361 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T129 | 576-584 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T130 | 732-740 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T121 | 83-91 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T122 | 165-173 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T123 | 245-253 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T124 | 710-718 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T125 | 832-836 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T126 | 924-932 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T328 | 122-128 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T329 | 190-191 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T330 | 565-566 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T331 | 708-709 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T332 | 765-769 | http://purl.obolibrary.org/obo/CLO_0001692 | denotes | a kd |
T333 | 863-865 | http://purl.obolibrary.org/obo/CLO_0001302 | denotes | 34 |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T159 | 677-686 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T160 | 786-793 | Chemical | denotes | epitope | http://purl.obolibrary.org/obo/CHEBI_53000 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T216 | 0-51 | Sentence | denotes | Antibody response to RBD is viral species-specific. |
T217 | 52-186 | Sentence | denotes | Effectively, none of the found SARS-CoV-2 antibodies nor the infected plasma cross-reacted with RBDs from either SARS-CoV or MERS-CoV. |
T218 | 187-290 | Sentence | denotes | In a study, 206 monoclonal antibodies specific to the RBD SARS-CoV-2 were identified in eight patients. |
T219 | 291-443 | Sentence | denotes | These mAbs are different in: antibody heavy and light chains, antibody clones, CDR3 length… which lead to different binding and neutralizing capacities. |
T220 | 444-535 | Sentence | denotes | ACE2 is out-competed with almost 100% efficacity by some mAbs such as P2B-2F6 and P2C-1F11. |
T221 | 536-699 | Sentence | denotes | Interestingly the latter and a moderate antibody P2C-1C10 seems to target the different epitopes, and they could be combined for synergistic antiviral effect [96]. |
T222 | 700-867 | Sentence | denotes | CR3022, a SARS-CoV RBD-specific antibody, can bind strongly with a kd of 6.3 nM to an epitope on RBD that does not overlap with the SARS-Cov-2 ACE-2 binding site [34]. |
T223 | 868-940 | Sentence | denotes | Despite its strong binding, CR3022 could not neutralize SARS-CoV-2 [97]. |
2_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
32450171-32065055-66454512 | 863-865 | 32065055 | denotes | 34 |